BridgeBio Launches Landmark ATTR Prevention Trial

BridgeBio Pharma is advancing treatments for transthyretin amyloid disease (ATTR) with its drug acoramidis, which aims to stabilize the transthyretin protein and prevent or delay disease onset in asymptomatic carriers. The company has initiated the ACT-EARLY clinical trial, enrolling around 600 participants to evaluate acoramidis' effectiveness in preventing ATTR-related cardiomyopathy and polyneuropathy. Recent data from BridgeBio's ATTRibute-CM study, to be presented at Heart Failure 2025, reveal improved clinical outcomes, quality of life, and notably a reduced incidence of atrial fibrillation events in patients treated with acoramidis. These findings highlight the potential of acoramidis not only to treat but also to prevent complications associated with ATTR, including atrial fibrillation, a common cardiac arrhythmia linked to poor outcomes. Meanwhile, other research underscores the complexity of atrial fibrillation management, emphasizing the need for better predictive tools such as phenotypic age metrics to estimate recurrence risk after radiofrequency ablation. Together, these studies reflect ongoing efforts to improve cardiovascular disease prediction, prevention, and treatment through innovative therapies and refined risk assessment models.